Company intelligence / Profile preview

Nisshin Kyorin Pharmaceutical

Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

Nisshin Kyorin Pharmaceutical was a Japanese pharmaceutical company established in 2003 as a joint venture between Nisshin Seifun Group and Kyorin Pharmaceutical. The company specialized in the development and commercialization of prescription drugs, with a strategic focus on the therapeutic areas of gynecology and dermatology. Its most prominent product was Lunabell, a combination therapy for dysmenorrhea associated with endometriosis. In 2008, Kyorin Pharmaceutical acquired the remaining 50% stake from Nisshin Seifun to consolidate its domestic operations, and the entity was officially merged into Kyorin Pharmaceutical Co., Ltd. in 2009.

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Biotech

Partnerships

Nisshin Seifun GroupKyorin Pharmaceutical

Beyond the preview

Go deeper on Nisshin Kyorin Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nisshin Kyorin Pharmaceutical.

Explore the full profile